Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis
Status:
Recruiting
Trial end date:
2026-10-12
Target enrollment:
Participant gender:
Summary
This is a multi-centre phase 2 open-label prospective study designed to assess the efficacy
and safety of ropeg patients with pre-fibrotic primary myelofibrosis or DIPSS
low/intermediate-1 risk myelofibrosis after 24 months of treatment.